GLP-1 Dosing and Titration: Why You Start Low
A plain-language look at why semaglutide and tirzepatide begin at doses too small to treat — and what the drug labels and clinical trials say about ramping up slowly.
If you have been prescribed a GLP-1 medication such as Wegovy (semaglutide) or Zepbound (tirzepatide), you may notice something surprising about the first weeks of treatment: the starting dose is deliberately small — small enough that it is not meant to do the main job yet. That is by design. Clinicians call the approach "start low, go slow," and it is written directly into these drugs' FDA labeling.
Why the starting dose isn't meant to treat
The most common side effects of these medicines are gastrointestinal: nausea, diarrhea, and related stomach complaints. The step-up schedule exists specifically to blunt them. Zepbound's FDA label is direct about the reason, instructing prescribers to follow the escalation schedule "for all indications to reduce the risk of gastrointestinal adverse reactions." Wegovy's label makes the same logic explicit in another way: it states that the lowest doses — 0.25 mg, 0.5 mg, and 1 mg — "are initiation and escalation dosages and are not approved as maintenance dosages." In plain terms, the first doses exist to let your body adjust, not to treat your condition.
The first doses exist to let your body adjust, not to treat your condition.
What the schedules actually look like
Each drug has its own cadence, but both climb in steps spaced about four weeks apart.
- Wegovy (semaglutide 2.4 mg) follows a fixed 16-week schedule0.25 mg once weekly, then stepping up every four weeks — 0.25 → 0.5 → 1 → 1.7 → 2.4 mg — reaching the 2.4 mg maintenance dose at week 17.
- Zepbound (tirzepatide) starts at 2.5 mg once weekly for four weeks (a treatment-initiation dose the label says is "not approved as a maintenance dosage"), then moves to 5 mg, and may rise in 2.5 mg increments no sooner than every four weeks up to a maximum of 15 mg.
- Zepbound's recommended maintenance doses are 5, 10, or 15 mg; for obstructive sleep apnea, only the 10 or 15 mg doses are used.
The reason for weeks between steps is to give the digestive system time to acclimate at each level before the next increase.
Pausing and stepping back are part of the plan
A crucial and sometimes overlooked feature of these schedules is that they are not one-way ratchets. The labels build in room to slow down. Wegovy's instructions say that if a patient does not tolerate a dose during escalation, prescribers should "consider delaying dosage escalation for 4 weeks," and if the top 2.4 mg dose proves too much, the maintenance dose "may be reduced to 1.7 mg once weekly." The same flexibility appeared in the large SELECT cardiovascular trial, where the protocol allowed escalation intervals to be extended, treatment to be paused, or lower maintenance doses to be used if side effects became unacceptable.
Major guidance echoes this. The American Diabetes Association's 2026 Standards of Care in Overweight and Obesity says obesity medications requiring dose escalation "should be initiated at a low dose and uptitrated gradually, as needed, based on tolerability and clinical response," and adds that the right maintenance dose for a given person "may not necessarily be the maximum approved dose." In other words, higher is not automatically better; the aim is the dose that balances benefit against side effects.
What the trials show
Clinical evidence helps explain why the graded approach matters. In a pooled tolerability analysis of semaglutide 2.4 mg, gastrointestinal side effects were mostly non-serious — 98.1% were mild-to-moderate — usually temporary, and "occurred most frequently during or shortly after dose escalation." Only 4.3% of participants permanently stopped the drug because of GI effects. That analysis also found the GI side effects accounted for less than one percentage point of the weight-loss difference versus placebo, meaning the discomfort itself was not doing the work of the weight loss.
The pivotal trials show both sides of the ledger — meaningful results alongside common early symptoms. In STEP 1, semaglutide started at 0.25 mg weekly and reached the 2.4 mg goal by week 16; average weight change at 68 weeks was −14.9% with semaglutide versus −2.4% with placebo. Nausea (44.2% vs 17.4%) and diarrhea (31.5% vs 15.9%) were the most common side effects, yet GI-related discontinuation stayed low at 4.5% (versus 0.8% for placebo) — a sign that the gradual schedule kept most people on treatment. In SURMOUNT-1, tirzepatide was titrated over about 20 weeks, with average weight change at 72 weeks of −15.0%, −19.5%, and −20.9% at the 5, 10, and 15 mg doses versus −3.1% for placebo; again, most side effects were gastrointestinal, mostly mild to moderate, and occurred "primarily during dose escalation."
The strategy is not unique to weight loss. In SELECT, semaglutide was prescribed to reduce cardiovascular risk using the same step-up approach (starting at 0.24 mg weekly and reaching 2.4 mg after 16 weeks). It lowered major cardiovascular events (6.5% vs 8.0%; hazard ratio 0.80, 95% CI 0.72–0.90), though more people discontinued for adverse events than on placebo (16.6% vs 8.2%) — a reminder that side effects remain real even with careful titration.
The bottom line
Starting low is not a hurdle to rush past; it is the mechanism that makes these drugs tolerable enough to stay on long enough to work. The early doses are meant to let your body adjust, the roughly four-week steps give it time, and the schedule is designed to bend — pausing, extending intervals, or settling at a lower dose — when side effects demand it. How fast to climb, when to hold, and where to stop are individual decisions that depend on how you respond.
- 01 DailyMed — Wegovy (semaglutide) FDA Prescribing Information, 2025 dailymed.nlm.nih.gov ↗FDA label, Dosage and Administration: 16-week fixed titration to 2.4 mg, initiation-dose language, and tolerability delays/step-downs.
- 02 DailyMed — Zepbound (tirzepatide) FDA Prescribing Information, 2025 dailymed.nlm.nih.gov ↗FDA label, Dosage and Administration: escalation to reduce GI adverse reactions; 2.5 mg start, 2.5 mg increments to 15 mg; 5/10/15 mg maintenance.
- 03 Wharton S, et al., Diabetes, Obesity and Metabolism, 2022 pubmed.ncbi.nlm.nih.gov ↗Pooled GI tolerability analysis of semaglutide 2.4 mg: 98.1% mild-to-moderate, transient, peaking during escalation; 4.3% GI discontinuation.
- 04 Pivotal semaglutide obesity trial: 16-week titration, −14.9% vs −2.4% weight at 68 weeks, nausea/diarrhea rates (via ACG evidence summary).
- 05 Jastreboff AM, et al. (SURMOUNT-1), N Engl J Med, 2022 pubmed.ncbi.nlm.nih.gov ↗Tirzepatide obesity trial: ~20-week escalation, −15.0%/−19.5%/−20.9% at 72 weeks (treatment-regimen estimand), GI events mainly during escalation (PubMed abstract).
- 06 Semaglutide cardiovascular-outcomes trial: same 16-week titration from 0.24 mg, MACE 6.5% vs 8.0% (HR 0.80, 95% CI 0.72–0.90), discontinuation figures.
- 07 ADA Standards of Care in Overweight and Obesity, 2026 guidelinecentral.com ↗Guideline endorsement of low-dose initiation and gradual uptitration; maintenance dose need not be the maximum approved dose (Guideline Central summary).
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
